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ABSTRACT 
This study investigated L-leucine conjugated chitosan as a drug delivery vehicle in terms of 
dispersibility and controlled release from a nanoparticulate dry powder inhaler (DPI) 
formulation for pulmonary delivery using diltiazem hydrochloride (DH) as the model drug.  
DH-loaded nanoparticles of chitosan and conjugate were prepared by water-in-oil 
emulsification followed by glutaraldehyde crosslinking. Nanoparticles were characterised by 
dynamic light scattering (DLS) for particle size, X-ray Photoelectron Spectroscopy (XPS) for 
surface composition, and by Twin Stage Impinger (TSI) for drug dispersibility. The 
controlled release of DH was studied in phosphate buffered saline (PBS, pH 7.3±0.2, 37 °C) 
using UV spectrophotometry. The fine particle fractions (FPFs) of conjugated chitosan with 
and without drug were higher than those of non-conjugated chitosan nanoparticles. The 
conjugate nanoparticles were superior to those of unmodified chitosan in drug loading, 
entrapment efficiency and controlled release profile. The higher dispersibility was attributed 
to the amphiphilic environment of the L-leucine conjugate and hydrophobic crosslinks and 
the release profile reflects the greater swelling. The conjugated chitosan nanoparticles could 
be useful, after appropriate testing for biodegradability and toxicity, as an alternative carrier 
for lung drug delivery with enhanced aerosolization and prolonged drug release from 
nanoparticulate DPI formulations.   
 
Keywords: nanoparticles, dry powder inhaler (DPI), pulmonary delivery, controlled release, 
chitosan, L-leucine, diltiazem hydrochloride 
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INTRODUCTION 
The pulmonary route is a convenient, non-invasive way to deliver drug both for local and 
systemic effects. It has been successfully exploited for drug delivery for the management of 
asthma and chronic obstructive pulmonary disease (COPD). Because of the unique features 
of the lung, such as its large surface area, high permeability and large blood supply, this route 
has great potential for systemic delivery of various types of drugs. Controlled release delivery 
is an important therapeutic strategy with many advantages over conventional treatment 
systems including extended duration of action, reduction in dosing frequency, improved 
management of therapy, improved compliance, reduction in side effects, and potential cost 
savings. Drug-encapsulated polymeric nanoparticles have been widely studied for site-
specific targeting and controlled drug release, including for the development of dry powder 
inhaler (DPI) formulations. Of various formulation strategies, polymer micro- and 
nanoparticles have drawn much attention for pulmonary delivery of drugs in controlled 
release form1, 2.  
 
The use of polymer nanoparticulate systems is promising for both drug transport to the lung 
and sustained drug action. By controlling breathing parameters and particle size, large 
amounts of an inhaled nanoparticle dose can be deposited specifically to the lower regions of 
the lungs. Nanoparticles can escape mucociliary clearance and recognition by alveolar 
macrophages 3. Using an animal model, in vivo deposition of voriconazole loaded PLGA 
nanoparticles delivered via a DPI  showed prolonged drug release after pulmonary delivery 2.  
 
Chitosan, a widely available natural biopolymer, has gained much attention as a matrix for 
micro- and nanoparticles for controlled release drug delivery systems. Chitosan’s properties 
include low toxicity, biocompatibility and biodegradability, and some additional attractive 
features such as mucoadhesiveness and trans-epithelial permeability enhancement encourages 
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researches to use chitosan in drug delivery 4. It is positively charged and has been found to 
improve drug absorption by opening the intercellular tight junctions of the lung epithelium 5. 
Successful delivery of insulin loaded chitosan nanoparticles into the deep lungs followed by 
the transport of the released drug to systemic circulation 6, 7. Lung delivery of  heparin 8, 
calcitonin 9, paclitaxel 10, cisplatin 11  encapsulated chitosan nanoparticles have been 
investigated. Various drug loaded chitosan nanoparticles have been demonstrated in terms of 
the enhanced mucoadhesivnes or cellular absorption upon lung delivery 7, 12. Nanoparticles of 
chitosan or chitosan coated PLGA nanoparticles containing different drugs for lung delivery 
have been studied 13-15.  Chitosan based DPI formulations of beclomethasone dipropionate16, 
salbutamol sulphate17  showed promising controlled release profiles. Therefore, these studies 
demonstrated the potential of chitosan for pulmonary drug delivery. The glucosamine residue 
of chitosan has a pKa value of 6-7, resulting in protonation of the amino groups in acidic 
media. As a consequence, chitosan dissolves in acidic solutions; but is insoluble in neutral or 
alkaline solutions. These chemical properties allow chitosan to play an effective role in 
controlling drug delivery.  
 
It has been demonstrated that L-leucine, an amphiphilic amino acid with surfactant-like 
properties can significantly enhance the aerosolization of drug from a DPI formulation 18. 
Attempts to physically combine chitosan as a release modifier with the aerosolization 
enhancing ability of L-leucine were very effective. For instance, Learoyd et al. 16 reported 
improved dispersibilities of a hydrophilic drug, terbutaline sulfate; a hydrophobic drug, 
beclomethasone dipropionate; and a combination of these drugs from chitosan-lactose-
leucine based DPI formulations. The formulations also showed a sustained release profile of 
up to 12 hours for beclomethasone dipropionate. Considering the promising effects of leucine 
as an aerosolization enhancer upon physical addition to chitosan nano/microparticles in DPI 
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formulations 19, our study was designed to examine the effects of chemical conjugation of 
leucine to chitosan on the dispersibility and controlled release of drug-encapsulated chitosan 
nanoparticles from a DPI formulation.  Recently, the chemical conjugation of L-leucine to 
chitosan has been reported and the derived nanoparticles displayed a low level of toxicity in 
lung epithelial cell lines20, which is favourable for pulmonary delivery. Due to the surfactant-
like properties of leucine and previous reports on the orientation of physically admixed 
leucine on the particle surface20, it was assumed that leucine conjugated to chitosan would 
provide an amphiphilic environment around the chitosan backbone and in turn would favour 
the dispersibility and controlled release of a hydrophilic drug from the engineered 
nanoparticles, as schematically shown in Fig. 1. In this figure the hydrophobic domain would 
be favoured at the surface when in air (as for delivery via DPI) and then in water the 
hydrophilic domain would be favoured at the surface, the chitosan would be swollen by water 
and facilitate drug delivery. 
 
This study is a continuation of our previous research20, where the chemical synthesis and 
characterization of leucine-conjugated chitosan, preparation of drug loaded nanoparticles and 
their toxicological studies have been demonstrated.  Herein, we demonstrate the effect of 
leucine chemically conjugated with chitosan on the dispersibility and prolonged release of a 
model drug diltiazem hydrochloride DH (a water soluble antihypertensive drug which 
undergoes extensive first pass metabolism following oral administration) from a drug-loaded 
nanoparticulate DPI formulation. The chitosan as nanoparticulate lung drug delivery has been 
selected in this study due to its low toxicity 20, 21 and compatibility with respiratory epithelial 
cells22. The main aim of this study is to understand the effect of leucine chemically 
conjugated with chitosan on the aerosolization and drug release mechanism from the 
nanoparticles.     
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MATERIALS AND METHODS 
Materials 
Low molecular weight chitosan (DDA 92%, MW 50-190 kDa) was purchased from Sigma-
Aldrich Pty Ltd (Australia). Chitosan-N-L-leucine.HCl (conjugate) was synthesized as 
previously described20.  Confirmation of chemical conjugation of L-Leucine to the amino 
group at C-2 of chitosan has been detailed in the published article. 20  Glacial acetic acid, 
hexane, diethyl ether and 50% aqueous glutaraldehyde were obtained from Merck, Australia. 
Glacial acetic acid was diluted in water to the required concentration before use. Paraffin oil 
heavy 68 (viscosity: 66.0-70.0 cST @ 40 °C) was supplied by Chem-Supply, Australia. Span 
80 was purchased from Professional Compounding Chemists of Australia. Diltiazem HCl 
(DH) was a gift from Alpha-Pharm, Australia. Phosphate-buffered saline (PBS) tablets (pH 
7.3±0.2 when dissolved in water as directed) were supplied from Oxoid, England.  
 
Preparation of nanoparticles 
Chitosan and conjugate chitosan nanoparticles loaded with DH were prepared using a 
modified glutaraldehyde crosslinking method 23. A schematic flow chart of the preparation 
method is shown in Fig.2. Briefly, for preparing blank chitosan nanoparticles, 2.5 mL of a 2% 
solution of chitosan in 2% acetic acid was added drop-wise at room temperature to 100 g 
heavy paraffin oil containing 1 mL span 80 and homogenized into a w/o emulsion at 11,000 
rpm for 10 min. The pH of the solution as this point was measured potentiometrically as 5.5. 
A 50% aqueous solution of glutaraldehyde (1 mL per 25 mg of chitosan) was added into this 
mixture and was stirred overnight at 5000 rpm and room temperature using an IKA® Eurostar 
Digital overhead stirrer (IKA® Works Inc.) for hardening the droplets into particles. The 
addition of the glutaraldehyde solution was done in 3 portions at intervals of 10 min, 1 h and 
2 h. The nanoparticles were then separated from the oil phase by centrifuging overnight at 
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5,000 × g using an Allegra X15R bench top centrifuge (Beckman-Coulter, Inc. USA) and 
washed 3 times with hexane to remove excess oil. Finally, the isolated particles were washed 
3-5 times with diethyl ether to remove residual glutaraldehyde, and dried under vacuum at 60 
°C. Although water and ethanol are excellent solvents for washing off residual 
glutaraldehyde, they were not considered appropriate for this purpose to avoid leaching of 
DH, which is highly soluble in these solvents. 
 
The above protocol was followed to prepare blank conjugate nanoparticles. However, being 
freely soluble in water, no acetic acid was needed for preparing the solution of the conjugate 
in water and the volume of glutaraldehyde solution added for hardening the droplets was 0.75 
mL per 25 mg of the conjugate. Fifty percent of the polymer was replaced by DH and all 
other conditions were kept unchanged during the entire process to prepare drug loaded 
chitosan and conjugate nanoparticles.  
 
Measurement of particle size, size distribution and surface zeta potential 
The primary particle size distribution of chitosan and conjugate nanoparticles was determined 
by dynamic light scattering (DLS) using a ZetaSizer Nano S instrument (Malvern Instruments 
Ltd., UK)  as described previously 20. Using this DLS, surface charges on nanoparticles were 
determined. The nanoparticle powders were dispersed in 0.1 mM KCl, following 10 min 
sonication and the zeta potential measurements were repeated in triplicate. 
 
 XPS analysis 
The XPS analysis of chitosan and L-leucine conjugated chitosan as well as their nanoparticles 
was performed using a Kratos Axis Ultra Spectrophotometer (Kratos Analytical, Manchester, 
UK) equipped with a monochromatized aluminium X-ray source (powered at 10 mA and 15 
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KV), 165 mm radius hemispherical analyser (HSA) and 8-channel electron multiplier 
(channeltron) detection system. Samples were mounted onto stainless steel sample holders 
using double-sided adhesive tape and the spectra were collected using an analysis area of 700 
 300 µm. Low-resolution wide scans (survey spectrum) in the binding energy scale (0–1200 
eV with 1.0 eV steps) were collected at a constant analyser pass energy of 160 eV to identify 
the elements present. High-resolution narrow scans (multiplex spectra) were collected at 20 
eV with 0.05 eV steps for O1s, N1s, C1s, and Cl2p to identify their chemical status. The data 
were processed using Casa XPS software Version 2.3.14.  Binding energies (BE) of the 
various elements were referenced to the C1s line at 285.0 eV. 
 
Determination of production yield, drug loading and entrapment efficiency  
The yields of nanoparticles were quantified as the percentage of anticipated yields. The total 
amount of nanoparticles obtained was weighed and the percentage yield was calculated using 
the following formula:  
 
Production yield (%) = ௐଵௐଶ × 100                                                  (1) 
where  W1 = weight of dried nanoparticle 
      W2 = sum of dry weight of the starting materials. 
 
To determine drug loading and entrapment efficiency, an aliquot (5 mL) of the external oil 
phase was centrifuged to remove the particles. Then, the free drug in the supernatant was 
extracted into an excess of PBS (1:4) and analyzed by UV spectrophotometry (Beckman 
Coulter DU 800 UV/Vis Spectrophotometer, USA) at 235 nm. The amount of drug in the 
supernatant was subtracted from the total amount of drug initially added for making 
nanoparticles. The drug loading and entrapment efficiency were calculated as follows: 
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Drug loading (%) = ୘୭୲ୟ୪	ୢ୰୳୥ି୊୰ୣୣ	ୢ୰୳୥୒ୟ୬୭୮ୟ୰୲୧ୡ୪ୣ	୵ୣ୧୥୦୲   100                                (2) 
Entrapment efficiency (%) = ୘୭୲ୟ୪	ୢ୰୳୥ି୊୰ୣୣ	ୢ୰୳୥୘୭୲ୟ୪	ୢ୰୳୥   100                  (3) 
 
In vitro dispersibility study 
The aerosolization efficiency of DPI formulations (chitosan and conjugate nanoparticles) was 
investigated in vitro using a twin stage impinger (TSI, Copley Scientific, Nottingham, UK) 
via a method described previously 24. A Rotahaler® (Glaxo Wellcome) was used as the DPI 
device and PBS as the collection liquid in the upper and lower stages of the apparatus. 
Approximately 7 mL of PBS was placed in stage-1 (S1) and 30 mL in stage-2 (S2) of the 
TSI. PBS was used to maintain a consistency with the spectrometric analyses made during 
the drug release study and determination of entrapment efficiency. The airflow through the 
TSI was controlled at 60±5 L/min by a vacuum pump (D-63150, Erweka, Germany) using a 
calibrated digital flow meter (Fisher and Porter, Model 10A3567SAX, UK). For each 
actuation, a size 3 hard gelatin capsule (Fawns and McAllan Pty Ltd., Australia), filled with 
approximately 20 mg of nanoparticle formulation, was inserted into the Rotahaler device, 
which was placed into a moulded mouthpiece attached to the TSI apparatus. The capsule was 
twisted to release the powder into the body of the DPI device. This procedure was repeated at 
least three times for each formulation. 
 
Each stage of TSI (Rotahaler, S1 and S2) was washed separately and samples were collected 
in appropriate vessels. The washings from each stage were filtered repeatedly for at least 5 
times through pre-weighed nylon filters of 0.20 µm pore size and 47 mm diameter 
(Phenomenex, USA) (that were dried at 60 °C until reaching a constant weight). The weight 
of this pre-weighed nylon filter was validated by filtering water (without nanoparticles) 
through it and drying at 60 °C until a constant weight was reached. This method was 
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validated using 3 blank filter papers with 3 replicate and an average constant weight of the 
dried filter papers was determined and used in nanoparticle quantification. Although 0.2 µm 
is a much higher pore size compared to the size of the prepared nanoparticles, repeated 
circulation of the liquid containing the particles through the filter enabled complete removal 
of particles, because of the tendency of particles to form agglomerates and gradually block 
the pores. The filtration was repeated until the filtrate became completely free from any sign 
of turbidity. The filters, with retained particles, were dried at 60 °C until a constant weight 
was reached. The weight of the nanoparticles deposited was determined by subtracting the 
weight of the blank filter from the total weight.  
 
The total amounts of nanoparticles collected from the inhaler, stage-1 (S1) and stage-2 (S2) 
are termed the recovered dose (RD).   
The emitted dose (ED) refers to the fraction of the RD delivered from the inhaler into stages 
1 and 2 expressed as a percentage:  
ED = ୗଵାୗଶ	ୖୈ   100                                                                              (4) 
The fine particle fraction (FPF) is defined as the fraction of the RD deposited in the stage-2 
of TSI expressed as percentage:   
FPF =  ୗଶୖୈ   100                                                                                (5)           
Using UV spectrometric analysis, the FPF and the fine particle dose (FPD, defined as the 
mass of drug) of DH deposited in the stage-2 of TSI, was determined. As described above, 
the collected volume of washings from each stage of TSI was adjusted to 50 mL and 
incubated with gentle stirring for an appropriate length of time (8 days for chitosan 
nanoparticles and 16 days  for conjugate nanoparticles)  to allow for the maximum drug 
release from nanoparticles.  The samples were filtered and the aliquots of supernatant were 
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analysed for drug content by UV spectrophotometry at 235 nm.  The length of the incubation 
period was decided on the basis of the maximum drug release from the two formulations.  
 
In vitro controlled release study 
Drug release from the nanoparticles was studied according to the method reported by Masotti 
et al. 25 with few modifications. Briefly, an aliquot of nanoparticles equivalent to 2.5 mg DH 
was incubated in 50 mL PBS (pH = 7.3±0.2, 37 °C) under gentle magnetic stirring (100 rpm). 
At fixed time intervals (0.5 h, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h and later every 24 h up to 30 days), 
the samples were centrifuged (5,000 rpm) and 5 mL aliquots of supernatant  were removed. 
An equal volume of fresh buffer was immediately added to replace each aliquot removed. 
The withdrawn samples were analysed by UV spectrophotometry. All measurements were 
performed in triplicate (n=3).  
To ascertain the release kinetics and the mechanism of release, the release data were analysed 
by fitting to commonly used mathematical models, viz. the zero order model, 1st order model, 
Higuchi’s square root model 26, Hixson-Crowell model 27 and Korsmeyer-Peppas model 28  
according to the following equations: 
Zero order model: F=kot                                                                     (6) 
1st order model: ln (1-F)=-k1t                                                              (7) 
Higuchi model: F=KHt1/2                                                                     (8) 
Hixson-Crowell model: 1-(1-F)1/3=k1/3t                                               (9) 
Korsmeyer-Peppas model: F=kK-Ptn                                                    (10) 
where F denotes cumulative fraction of drug released at time t.  k0, k1, kH, k1/3 and kK-P are the 
apparent release rate constants of the respective mathematical models. n is the release 
exponent of the Korsmeyer-Peppas model, indicative of the mechanism of drug release. n ≤ 
0.45 corresponds to a Fickian diffusion (case I transport), 0.45 < n ≤ 0.89 to an anomalous 
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(non-Fickian) transport, n = 0.89 to a zero-order (case II) release kinetics, and n > 0.89 to a 
super case II transport. Case II and super case II transports indicate involvement of polymer 
chain relaxation and erosion in drug release. 
 
The initial loading dose (DL) providing for prompt achievement of the desired blood level 
and the desired maintenance dose release rate (MDR) to maintain the desired blood level over 
extended periods of time can be given by the following equations: 
DL = Cd.Vd/F                                                                                        (11) 
MDR = ke.Cd.Vd                                                                                   (12) 
where Cd is the desired blood level, Vd is the apparent volume of distribution, ke is the first 
order rate constant for overall drug elimination and F is the fraction of the dose absorbed. 
 
Statistical analysis 
All the measurements and experiments were performed in triplicate and the results were 
expressed as the mean ± standard error (SE). The statistical significance of the differences 
was assessed by one-way analysis of variance (ANOVA) with post-hoc (Tukey-HSD) test for 
multiple comparisons; differences with a p-value of 0.05 or less were considered as 
significant. 
 
RESULTS 
Particle size distribution 
The zetasizer analysis of both the drug-loaded and blank chitosan and conjugate nanoparticles 
showed multi-modal size distributions (Fig. 3). The blank chitosan nanoparticles showed bi-
modal distributions (Fig. 3 A), comprising a population of particles around 32 d.nm size 
range and another around 388.7421.2 d.nm. The blank conjugate nanoparticles had a 
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bimodal distribution (Fig. 3 B) with a population of particles having a mean diameter of 
19.860.38 d,nm and the other of 509.5419.1 d.nm; the overall Z-average was 42.341.04. 
Drug-loaded chitosan nanoparticles had a bi-modal distribution (Fig. 3 C), comprising a 
population of particles with a mean diameter of 32±1.3 d.nm and another population of 
526±26.2 d.nm. The overall Z-average size was 64±2.6 d.nm. The drug-loaded conjugate 
nanoparticles showed a tri-modal distribution (Fig. 3 D) with mean sizes of 1±0.0 d.nm, 
30±1.9 d.nm, and 497±21.3 d.nm; the overall Z-average being 19±2.0 d.nm.  
 
Surface analysis of materials and nanoparticles by XPS 
Table 1 gives the calculated atomic concentration of the original chitosan material with 
degree of de-acetylation (DDA) of 92%, and the L-leucine conjugate (with a degree of 
substitution of 0.74 as determined gravimetrically)20 as well as the nanoparticles obtained by 
glutaraldehyde crosslinking. The structures of the chitosan and conjugate materials used for 
these calculations are shown in Figures 4.1 and 4.2.  (Note that XPS does not measure H 
atoms so these do not appear in any calculated values). The structure of the crosslinks formed 
in glutaraldehyde crosslinking of amino functional groups is pH dependent. For the 
calculation of nanoparticle surface composition, the glutaraldehyde crosslinking reaction is 
assumed to have occurred under acidic conditions (based on the measured emulsion pH of 5.5 
at the time of addition) to replace all amino groups (-NH2) on the chitosan and conjugate 
nanoparticles’ surfaces with imine groups. Furthermore, in the case of the conjugate, since 
not all amino groups have been substituted with L-leucine, the crosslinking can occur in three 
different ways:  
 between free amino groups of glucosamines 
 between the amino groups of conjugated L-leucine 
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 “cross coupling” between a free amino group of a glucosamine and an amino group of 
conjugated L-leucine. 
In spite of the degree of substitution of L-leucine on the chitosan backbone, the total number 
of amino groups available for crosslinking remains the same as in the original chitosan since 
each amino group of the L-leucine conjugate has resulted from reaction at an amino group on 
the chitosan (Figures 4.1 and 4.2).Further molecular structure information was obtained by 
multiplex XPS scans and allowed the observation of [N+] from the -NH2.HCl group of the 
chitosan-leucine conjugate as well as [–C=O] that may have formed due to oligomerisation of 
glutaraldehyde to give a short chain length structure with terminal aldehyde groups29. 
 
Production yield, drug loading and entrapment efficiency  
The yield, entrapment efficiency and drug loading of chitosan and conjugate nanoparticles 
are summarized in Table 2. 
 
Surface charge of nanoparticles 
The surface charge measured by DLS showed all chitosan nanoparticles (blank, conjugate 
and drug loaded) were highly positively charged and the amount of charge decreased 
significantly after drug loading (Table 3). Although statistically insignificant, the surface 
charge of chitosan increased upon conjugating with leucine.  The reduction of surface charge 
with drug loading implied that the nanoparticle surface positive charges were masked due to 
the accumulation of some drug on the nanoparticles surface. 
 
In vitro aerosolization study 
Table 3 summarises the data representing RD, ED and FPF of blank and drug-loaded chitosan 
and conjugate nanoparticles. As per gravimetric analysis, the total amounts of the 
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nanoparticles recovered from all the stages of TSI ranged between 74 and 87% of the loaded 
doses (Table 3). The fraction of the total dose emitted in the upper and lower stages was in 
the range of 73-85%, with the exception of the blank chitosan nanoparticles that had a 
relatively low emitted dose of 62% only. Statistical analyses showed that there was no 
difference between emitted doses of drug-loaded chitosan and conjugate nanoparticles 
(73±1.96% vs. 79±2.52%, p>0.05), but the emitted dose of blank conjugate nanoparticles was 
significantly higher than that of blank chitosan nanoparticles (85±0.94% vs. 62±0.39%, 
p<0.05). The FPFs of pure chitosan and conjugate chitosan formulations were 19 and 24%, 
respectively. The FPFs of both blank and drug-loaded conjugate nanoparticles were 
significantly higher than those of corresponding unmodified chitosan nanoparticles (24±0.8% 
and 21±0.7% vs. 19±1.01% and 15±1.5%, respectively; p<0.05). The drug-loaded 
nanoparticles of both chitosan and the conjugate had lower FPFs than the corresponding 
blank nanoparticles (15±1.5% and 21±0.7% vs. 19±1.01% and 24±0.8%, respectively); 
however, the analysis of variance showed an insignificant difference (p>0.05).   Significantly 
(p>0.05) higher FPF and FPD of DH determined by UV analysis from drug loaded conjugate 
chitosan (21% & 0.31 mg) compared to that of blank chitosan (16% & 0.09 mg), were 
observed.    
 
In vitro drug release study 
The release of DH from drug-loaded chitosan and conjugate nanoparticles in phosphate 
buffered saline (pH 7.3±0.2) at 37 °C as cumulative % of drug released and retained at 
different time points according to various kinetic models i.e., zero order, first order, Higuchi 
26 and Hixson-Crowell 27 are presented in Fig. 5. To gain an insight into the mechanism of 
drug release, the data were also analysed by the Korsmeyer-Peppas model 28 (Table 4).  As 
shown in Fig. 5, both chitosan and conjugate nanoparticles exhibited a large initial burst 
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followed by a controlled release at a slow rate over a period of approximately 1-2 weeks. The 
drug loaded chitosan nanoparticles showed an initial burst release of 16±0.32% and a 
maximum cumulative % release of 23±0.31% at the end of 192 hours (8 days). The 
corresponding values for drug loaded conjugate nanoparticles were 31±1.98% and 52±1.55%, 
respectively. The release from conjugate nanoparticles continued for a longer period and 
reached a maximum at the end of 384 hours (16 days). Although the experiment was 
continued for a period of 30 days, no further increase in the amount of drug released was 
observed after 8 and 16 day periods from chitosan and conjugate nanoparticles, respectively. 
 
To determine the goodness of fit of various models, the release data were analysed by simple 
linear regression (using the data points until the time at which cumulative drug release 
reached its maximum i.e. 8 and 16 days for chitosan and conjugate nanoparticles, 
respectively). The determination coefficients (r2) and release rate constants determined by 
fitting the release data to various kinetic models and regression analysis are presented in 
Table 4. For the Korsmeyer-Peppas model, the table records the release exponent, n. 
 
DISCUSSION  
Preparation of chitosan and conjugate nanoparticles 
Of various techniques reported in the literature, the emulsification-glutaradehyde crosslinking 
method was chosen for this work. The emulsification method provides access to particles in 
the desired size range by adjusting the time and/or speed of stirring. In addition, it also allows 
fabrication of particles with a more optimized release of the encapsulated drug by ensuring a 
uniform dispersion of the drug throughout the polymeric matrix 30. Glutaraldehyde cross-
linking has been reported as an effective means for hardening chitosan droplets into solid 
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particles and controlling drug release31. In addition, this technique has an advantage of 
avoiding the use of heat which could be harmful, if sufficiently high, for a drug like DH.  
 
Particle size and size distribution 
Zetasizer analysis of both drug loaded chitosan and conjugate nanoparticles (Figure 3) 
showed a multimodal distribution with a population of particles having Z-averages in the 
range of 30-32 d.nm. There was another population with Z-averages at a much higher size 
range (497 and 526 d.nm), which reflects formation of agglomerates of small individual 
particles. It is noteworthy that the drug loaded chitosan nanoparticles showed a bimodal 
distribution whereas the drug loaded conjugate nanoparticles produced a trimodal (an 
additional peak at 1.0 d. nm) distribution with lower intensity. Agglomeration is a common 
phenomenon with nanoparticles, which results from large surface area and the associated 
high surface free energy of particles in this size range. The high polydispersity index (1.00) 
of these samples also gives an indication of a high agglomeration tendency of nanoparticles 
and therefore, we suggest the lung deposition of nanoparticles is likely to be dependent on 
both the size of primary nanoparticles or agglomerates of nanoparticles. 
 
Surface analysis of nanoparticles 
The chitosan-leucine conjugate as synthesised and before nanoparticle formation is 
characterized by the appearance of the -N+ species in XPS multiplex spectra (Table 1). It may 
be seen that [N+] is approximately equal to [Cl] so is diagnostic of the number of NH2.HCl 
species formed on functionalization of chitosan as shown in Figure 4.2. The spectral analysis 
in the N1s region has also been used to determine the degree of substitution of the L-leucine 
on the amino group of chitosan since the residual primary amine groups can be measured and 
then compared to the original concentration in the starting material. The ratio of these 
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concentrations is 0.11 indicating a degree of substitution of 0.89.  Figure 4.2 also shows that 
the effect of conjugation should be to render the surface of the nanoparticle more 
hydrophobic than chitosan alone due to the isobutyl terminal group of leucine, which 
contributed to enhance the dispersibility of conjugated nanoparticles that discussed later 
(Table 3).but the amphiphilic nature of the leucine conjugate means that it is likely to be 
responsive to the environment in which it is placed. It is interesting to compare the degree of 
substitution found by XPS surface analysis (0.89) to that reported by a bulk analysis of the 
material as synthesised (0.74) 20. The calculated values shown in Table 1 are based on a 
degree of substitution of 0.74 from microanalysis. The surface analysis indicates a greater 
concentration of the more hydrophobic conjugate at the surface compared to the bulk, when 
the sample is measured dry and in vacuum (XPS conditions) supporting the behaviour as 
hypothesised in Figure 1. This figure depicts the leucine-conjugated chitosan nanoparticles showing 
hydrophilic and hydrophobic domains and the hypothesised nanoparticle surface with a conformation 
that changes to be hydrophobic t-butyl group in air for particle dispersion and hydrophilic NH2-
(C=O)NH- domain that will associate with water for drug release.  
 
Production yield, drug loading and entrapment efficiency  
As shown in Table 2, the yields of both chitosan and conjugate nanoparticles were apparently 
more than 100% (chitosan, 125±6% and conjugate, 119±5%). This is attributed to an increase 
in the mass of the starting polymers due to incorporation of glutaraldehyde moieties; 
however, residual moisture left in the particles might also have contributed to the increase in 
weight. The drug entrapment efficiencies of chitosan and conjugate nanoparticles were 
38±1% and 46±1%, respectively (Table 2).  The actual reason behind this low entrapment 
was unclear; however, the following factors may be considered as potential causes. Firstly, 
the small size of the prepared nanoparticles might have contributed to the low entrapment of 
drug.  The capacity of drug entrapment is associated with particle size, which depends upon 
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the polymer concentration 32. As the prepared particles are very small, we suggest the 
obtained drug entrapment was the maximum capacity for these nanoparticles. Secondly, 
during the cross-linking and hardening process, water was exuded from the particles taking 
along the dissolved drug; this could also contribute to the decrease in the incorporation 
efficiency 33. Thirdly, some drug was probably partitioned out to the external oil phase 
although the solubility of the drug, DH in oil was limited, the oil phase was still able to 
accommodate a considerable amount of the drug because of its large volume (79 times higher 
than the drug-containing water phase). The higher entrapment efficiency and drug loading of 
conjugate nanoparticles compared to chitosan nanoparticles (46±1% and 20±1% vs. 38±1% 
and 16±1%, respectively) could be attributed to the higher solubility of the conjugate in water 
that enabled its better association with the water soluble drug, DH. This is because the 
entrapment of drug is dependent on the successful molecular-level association of the drug 
with the polymer 34. The percentage of drug loading obtained for chitosan and conjugate 
nanoparticles was 16±1% and 20±1%, respectively (Table 2). As explained above, this 
apparently low % loading was due to the loss of some drug due to partitioning into the 
external oil phase and probable low entrapment of drug due to very small size of particles. 
However, these values could be even higher if the particle yield did not exceed 100% 
(chitosan, 125 ± 6% and conjugate, 119 ± 5%) owing possibly to glutaraldehyde cross-
linking. 
 
In vitro aerosolization study 
The aerosolization performance of different formulations was characterised in terms of RD, 
ED, FPF and FPD.  As per gravimetric analysis, the recovered doses from different 
formulations were between 74% and 86% (Table 3), indicating that about 15 to 25% of the 
actuated particles retained in the inhaler device and stages of the TSI. Sticking of some 
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particles to the glass surfaces of the TSI chambers might have primarily accounted for this 
loss. For drug-loaded particles, drug released from the particles in the collecting solvent 
(PBS) might also have some contribution to the observed loss of particles.  
 
The gravimetric method was used to determine the FPF of nanoparticles with and without 
drug loading; however, it was assumed that some drug washed away during filtration and 
washing, which eventually affected the FPF of nanoparticles containing DH. Therefore, the 
FPF of DH loaded chitosan and conjugate chitosan nanoparticles determined by the 
gravimetric method are comparatively less than that of the real values. A UV-
spectrophotometric method was also applied to determine the FPF and FPD of drug from 
DH- loaded chitosan and conjugate nanoparticles. In this case, the nanoparticles collected 
from the different stages of TSI were incubated in PBS (at 37ºC) solution and the drug 
allowed to be released. The release study for determining the FPF/FPD was carried out only 
for 16 days as the drug release from nanoparticles continued even after 30 days (refer to the 
release study). Therefore, it should be noted that the FPFs and FPDs of the model drug 
determined by UV analysis are not the final amounts of drug released from the nanoparticles.  
 
The emission of particles from the inhaler device was satisfactory for most formulations with 
the values ranging from 73 to 85% (Table 3). However, blank chitosan particles showed a 
relatively poor performance and the emission was found to be significantly lower than the 
corresponding conjugate particles (62±0.39% vs. 85±0.94%; p<0.05) (Table 3). This 
difference in emission may be explained by surface changes (reflecting the amphiphilic 
environment created by conjugated leucine around the chitosan backbone), or a less smooth 
surface of nanoparticles, as demonstrated in previously published article20, which are thought 
to dominate in reducing the interparticle interactions and increasing the aerosolization of the 
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particles. Very recently, the reduction in adhesion forces between a sulbutamol sulfate drug 
probe and leucine coated polycaprolactone (PCL) microcarriers has been reported 35. It was 
demonstrated that the leucine coatings altered the hydrophobic nature of the PCL surfaces, 
which reduced the adhesion forces between the two surfaces. The influence of surface 
hydrophobicity in the particle interactions is not clear; however, the enhanced dispersibility 
of particles was probably due to both the hydrophobic surface caused by the glutaraldehyde 
crosslinkers and by the presence of the amphiphilic leucine on the surface, as demonstrated in 
Figure 1. Here in this figure, it can be explained that the leucine-conjugated chitosan 
nanoparticles showing both hydrophilic and hydrophobic domains (depending on the 
surrounding media) and the nanoparticle surface with a conformation that changes to be 
hydrophobic t-butyl group (in air) that reduced the particle interactions and improved 
aerosolization.   
 
The FPF of conjugated chitosan nanoparticles was significantly higher (p = 0.004) compared 
to that of non-conjugated chitosan nanoparticles, which revealed that the conjugation of 
leucine with chitosan played a significant role in enhancing the dispersibility. Although drug-
loaded chitosan and conjugate nanoparticles showed equivalent emission from the DPI 
formulation, both the blank conjugate and the drug-loaded conjugate nanoparticles  showed a 
significantly (p<0.05) higher FPF than corresponding chitosan nanoparticles (24±0.8% and 
21±0.7% vs. 19±1.01% and 15±1.5%, respectively) (Table 3). The dispersibility of blank 
nanoparticles of both chitosan and conjugate, showed higher FPF than corresponding drug-
loaded nanoparticles (19±1.01% and 24±0.8% vs. 15±1.5% and 21±0.7%, respectively; 
p>0.05). The highest FPF (24%) of leucine conjugated chitosan nanoparticles was influenced 
by the presence of the hydrophobic t-butyl group of leucine on the particle surface, as 
explained earlier in Fig. 1, that reduced the particle cohesive forces. No published articles 
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have demonstrated the effect of leucine conjugation with chitosan on particle dispersibility 
from nanoparticulate DPI formulations. This outcome, investigated for the first time by our 
group, is novel and supported our proposed hypothesis. Additionally, the surface charge on 
the nanoparticles played a significant role in particle dispersion. Chitosan is a cationic 
polysaccharide and the gluteraldehyde cross-linked chitosan nanoparticles without drug 
loading were highly positively charged (37.8 mV), which increased (39.2 mV, Table 3) upon 
leucine conjugation. The higher FPF (24%) observed from the blank conjugated chitosan 
nanoparticles could be due to the higher surface positive charge (Table 3) that contributed to 
the electrostatic repulsive force among the particles. The higher FPF of drug loaded 
conjugated chitosan nanoparticles were also observed due to the observed higher surface 
charge (35.2 mV) compared to the drug loaded unconjugated chitosan (32.3 mV). The 
intrinsic surface positive charge of chitosan nanoparticles might contribute to enhance the 
deagglomeration process of nanoparticles resulting in increased FPF with increased charge. 
Drug loaded blank and leucine conjugated chitosan nanoparticles showed reduced FPF 
compared to those of nanoparticles without drug loading. The reason behind this was due to 
the masking of nanoparticle surface positive charge by the adhered drugs on the nanoparticle 
surface.  
 
The lower FPF of drug-loaded nanoparticles (both unconjugated and conjugated chitosan)  
might be due to a higher agglomeration tendency or increased capillary forces caused by 
incorporation of DH, a highly water-soluble drug, that were adjoined onto the surface of 
chitosan nanoparticles (but below detectability by XPS). The adjoined drug layers onto the 
nanoparticle surfaces might interfere with the hydrophobic nature of the surface, resulting in 
increased surface cohesion forces and thereby reduced dispersibility/FPF.  The tendency of 
increased agglomeration of chitosan-based microspheres upon the addition of a hydrophilic 
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drug, propranolol hydrochloride has been reported 36. The FPD of DH from drug loaded 
conjugate chitosan (0.31 mg) was more than 3 times higher than that from drug loaded 
chitosan nanoparticles (0.09 mg), which demonstrates the better dispersion behaviour of 
leucine conjugated chitosan (Table 3). This outcome further supports the superiority of 
conjugate chitosan over the parent chitosan in drug aerosolization and dispersion.   
 
In vitro drug release study 
As presented in Fig. 5, although the rate and extent of drug release varied, both chitosan and 
conjugate nanoparticles showed a bi-phasic drug release with a large initial burst release from 
the surface followed by a slow, controlled release due to the dissolution and diffusion of 
dissolved drug through the swollen rubbery chitosan and conjugated chitosan matrices over a 
period of 8 and 16 days, respectively. The initial burst release accounted for 16 ± 0.3%, and 
31 ± 1.9% of drug from chitosan and conjugate nanoparticles, respectively within the first 30 
min, leaving 84 ± 0.6% and 69 ± 3.4% in the particles potentially available for slow, steady 
release. This kind of bi-phasic release might prove useful to satisfy the pattern of release 
required of a sustained release formulation to quickly achieve a therapeutic blood level (burst 
release) and maintain it over time (controlled release). Similar patterns of release for various 
drugs from chitosan particles made by glutaraldehyde crosslinking 37 have also been reported.   
Both the initial burst and total release from conjugate nanoparticles were approximately 
double that from chitosan nanoparticles (31% and 52% vs. 16% and 23%) (Fig.5). This can 
be attributed to the improved aqueous solubility shown by the conjugate compared to the 
unconjugated chitosan. While chitosan required overnight stirring with dilute acetic acid for 
complete dissolution, the conjugate dissolved immediately upon adding to water.  
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Therefore, the higher the drug loading, the more the drug dissolved in the hydrated polymeric 
matrix. This would have resulted in a higher diffusional driving force and in turn caused a 
faster drug release from the conjugate nanoparticles. Similar reasoning has been made by 
Patel et al. 38 to explain the release of another hydrophilic drug, propranolol hydrochloride 
from a chitosan-based matrix.  Besides exhibiting a higher rate and extent of drug release, the 
conjugate nanoparticles also continued releasing drug for a period twice as long as was 
shown by chitosan nanoparticles (16 days, 52% vs. 8 days, 23%) (Figure 5). Two factors 
could have contributed to this. Firstly, the conjugate matrix had a higher percentage of drug 
loading (20±1% vs. 16±1%) in the nanoparticles, and secondly, the loaded hydrophilic drug 
inside the particles, upon dissolution, would take a long time to cross the hydrophobic 
environment dominating onto the surface, resulting in a longer period of drug release from 
the conjugated nanoparticles.   
 
The release of DH both from chitosan and conjugate nanoparticles was not complete even 
after 30 days, leaving 77% and 48% of drug, respectively, still unreleased (Figure 5). This is 
attributed to binding of a fraction of incorporated drug to some components of the matrix 
through electrostatic or covalent interaction39. An incomplete release (~50%) of BSA due to 
the interaction of the drug with the aldehyde moieties of the glutaraldehyde crosslinks has 
also been reported 40. It is noted that there is evidence from XPS (Table 1) for aldehyde 
groups on the surface of the chitosan and conjugate nanoparticles which arise as part of 
crosslinking reactions. Based on the observed FPDs of DH from drug loaded chitosan and 
conjugate chitosan nanoparticles (Table 3), the amounts of drug released from the 
formulations were calculated to be 0.01 µg/mL/hr and 0.02 µg/mL/hr, respectively. Thus, the 
DH loaded conjugated chitosan nanoparticles showed a two-fold higher drug release 
compared to that of drug loaded unconjugated chitosan nanoparticles, which further 
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demonstrated the superiority of conjugate chitosan over unconjugated chitosan. Using animal 
models, further investigations are warranted to understand the drug release from chitosan 
nanoparticles and subsequent absorption of drugs from the lungs. 
 
At present, the degradation of chitosan or its derivatives in biological fluids especially in lung 
fluids is not fully understood. The degradation of this polymer depends upon the molecular 
weight, degree of deacetylation of polymer, type of crosslinking agents used for nanoparticle 
preparation, concentrations of polymer and enzyme (lysozyme)7, and pH of the media22, 41-43. 
For example, Grenha et al.7 studied the degradation of chitosan (Protasan® 213 Cl, degree of 
deacetylation 86%) NPs crosslinked with TPP incubated in lysozyme solution in PBS (pH 
7.4) at 37°C. The incubation of NPs with lysozyme solution (0.2mg/mL; maximum lysozyme 
concentration in human tracheobronchial secretions) led to the NPs size reduction of 80 nm in 
90 minutes and size reduction was 140 nm when the concentration of lysozyme was increased 
to 8 mg/mL.  Significant reduction in NPs size occurred in first 5 minutes and the degradation 
was accelerated at high concentration of lysozyme. The rate of degradation of glutaraldehyde 
crosslinked chitosan is greater than that of tripolyphosphate (TPP) crosslinked chitosan (both 
high and low molecular weight) nanoparticles 44. Therefore, it is not straightforward to get a 
clear understanding on the degradability of the prepared nanoparticles in lung fluids. In our 
studies, leucine conjugated chitosan nanoparticles, made with glutaraldehyde crosslinker, 
showed higher drug solubility and release, which indicated that it could be more degradable 
in lung fluids. However, biodegradability studies in biological fluids are warranted to confirm 
the duration of NPs degradation. 
 
Kinetics of drug release 
Very little is known about the kinetics of inhaled drugs. To date the pharmacokinetics of 
pulmonary delivery of DH loaded chitosan (conjugated or non-conjugated) nanoparticles has 
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not been investigated. For elucidating the kinetics of drug release from both the chitosan and 
conjugate nanoparticles, the obtained in vitro data were fitted to 4 different kinetic models:  
zero-order, 1st order, square root of time or Higuchi model 26 and Hixson-Crowell model 27 
(Table 4).  Of these, the first three models are used for studying kinetics of diffusion-
controlled release from a matrix-type system, while the Hixson-Crowell model is used to 
describe dissolution–type release kinetics where the drug is released by dissolution with 
change in the surface area or diameter of the particles45. Literature reports suggest that 
controlled release of water soluble drug from chitosan-based systems in PBS/alkaline pH is 
governed by diffusion of the drug through hydrated swollen matrix46. From the r2 values 
recorded in Table 4,  it can be inferred that, after the initial burst, the release of the drug from 
both chitosan and conjugate nanoparticles followed Higuchi’s square root of time kinetics as 
correlation values showed a good fit to this model indicative of drug release by diffusion.  
This is in agreement with previous reports on drug release kinetics of chitosan microparticles 
46. The release rate constants (KH) determined by fitting the data to the model were 0.4709 × 
10-2 h-1 for chitosan nanoparticles and 1.1159 × 10-2 h-1 for conjugate nanoparticles (Table 4). 
The small values of the rate constants further confirmed that, after the large initial burst, the 
drug release from the nanoparticles proceeded at an extremely slow rate.  
 
To gain some insights into the corresponding mechanism of drug release, the release data 
were applied to the semi-empirical Korsmeyer-Peppas model 28. This model uses the value of 
the release exponent (n) obtained from the slope of a plot of log % cumulative release versus 
log time in order to characterize different release mechanisms. In theory, if n is 0.45 or less, 
the release mechanism is considered to follow Fickian diffusion, where drug release occurs 
through usual molecular diffusion because of a concentration (or chemical potential) gradient. 
Higher values of n between 0.45 and 0.89 indicate non-Fickian or anomalous transport, where 
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release is controlled by a combination of diffusion and polymer relaxation/erosion. Moreover, 
when n reaches a value of 0.89 or above, the mechanism of drug release involves polymer 
relaxation and chain disentanglement/erosion and the rate does not change over time 47. As 
shown in the Table 4, application of drug release data to the model and regression analysis 
resulted in a good fit giving coefficient of determination (r2) values of 0.9611 for chitosan 
nanoparticles and 0.9709 for conjugate nanoparticles.  The values for release exponent (n) 
were found to be 0.0568 and 0.0856, for chitosan and conjugate chitosan nanoparticles, 
respectively. This suggests that after the initial burst, the release of drug from both the 
formulations was controlled by Fickian diffusion through hydrated polymeric matrix. 
 
Overall, this study demonstrated the superiority of leucine conjugated chitosan nanoparticles 
in terms of higher aerosolization due to the surface hydrophobic nature caused by leucine.  
The aim of this preliminary study is to lay the groundwork for future research to optimize the 
dispersibility and controlled release of drugs from nanoparticulate DPI formulations.  If there 
is no enhanced uptake through pulmonary delivery, the developed formulation probably 
requires a large amount of the prepared drug encapsulated nanoparticles to be delivered into 
the lungs to produce therapeutic benefit and that may pose a safety concern. However, low 
toxicity of chitosan nanoparticles has been demonstrated elsewhere20, 21. Therefore, the 
conjugated chitosan nanoparticles could be useful as an alternative carrier (subject to 
appropriate testing for biodegradability and inflammatory response) for lung drug delivery 
with enhanced aerosolization and prolonged drug release from nanoparticulate DPI 
formulations. The results of this study may be helpful for investigating the formulation of 
other drugs encapsulated in leucine conjugated chitosan for lung delivery with better 
dispersibility and sustained release profile. Using animal models, further investigations are 
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warranted to understand the drug release from chitosan nanoparticles and subsequent 
absorption of drugs from the lungs. 
 
CONCLUSIONS 
This study demonstrated the potential of chitosan-N-L-leucine conjugate, a newly synthesized 
water-soluble derivative of chitosan, as a matrix for enhancing the dispersibility of 
nanoparticles from a nanoparticulate DPI formulation. The enhanced dispersion (the novelty 
of this study) of conjugated chitosan NPs was attributed to the surface hydrophobicity 
provided by the hydrophobic domain (t-butyl group) of conjugated L-leucine, and 
glutaraldehyde crosslinks formed on the nanoparticles surface. The outcome revealed the 
superiority of L-leucine conjugated chitosan nanoparticles over those of parent chitosan in 
terms of dispersibility, entrapment efficiency, drug loading, and release profile suggesting 
their potential as a prolonged release DPI formulation. The promising fast and prolonged 
drug release from leucine-conjugated nanoparticles was associated with the nature of the 
cross-links as well as the amide groups of the leucine-conjugate crosslink that gave the H-
bonding sites for water, which influenced a greater surface swelling. This study provided new 
insights on the application of leucine-conjugated chitosan nanoparticles for the pulmonary 
delivery of drugs from DPI formulations with enhanced dispersibility and prolonged release.  
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Figures 
 
 
 
Figure 1. Schematic of leucine-conjugated chitosan nanoparticles showing hydrophilic and 
hydrophobic domains and the hypothesised nanoparticle surface with a conformation that 
changes to be hydrophobic in air (for DPI dispersion) and hydrophilic in water (for drug 
delivery). In water the hydrophobic t-butyl group is rotated away from the surface towards 
the bulk so the hydrophilic NH2-(C=O)NH- domain of L-leucine is available to associate with 
water. Note that this diagram shows only the deacetylated chitosan units which constitute 
92% of the repeat groups. 
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Figure 2. Preparation of chitosan and conjugate nanoparticles 
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Figure 3. Particle size distribution of A) blank chitosan nanoparticles, B) blank conjugate 
nanoparticles, C) drug-loaded chitosan nanoparticles and D) drug-loaded conjugate 
nanoparticles. The sizes are presented as d.nm (hydrodynamic diameter in nm, n = 3).  
  
A B 
C D 
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Fig. 4.1   
                 
Fig. 4.2    
 
Figure4. Structures used to calculate composition of nanoparticles and precursor 
materials. Figure 4.1. Structure of chitosan showing residual N-acetyl groups. For the 
sample used: x=0.92; y=0.08;  Figure 4.2. Structure of chitosan-leucine conjugate.  
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Figure 5. In vitro release profiles of diltiazem hydrochloride from chitosan and conjugated 
chitosan nanoparticles (n=3, data presented as mean ± S.E).  
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Tables 
 
Table 1: Calculated and measured surface atomic composition from XPS analysis of chitosan 
with 92% DDA, chitosan- leucine conjugate and glutaraldehyde-crosslinked nanoparticles as 
well as particular diagnostic species (-N+ and –C=O) seen in multiplex spectra. 
Sample [C] [O] [N] [Cl] [N+] [C=O]
Chitosan (calculated) 54.8 36.3 8.9 0.0 0.0 0.0 
Chitosan (measured) 63.0 28.6 7.3 1.0 0.8 0.0 
Chitosan- leucine (calculated) 59.0 27.4 9.7 3.9 3.9 0.0 
Chitosan- leucine (measured) 61.0 25.7 9.3 3.4 3.0 0.0 
Chitosan nanoparticle (calculated) 62.5 30.1 7.4 0.0 0.0 0.0 
Chitosan nanoparticle (measured) 74.8 23.7 1.2 0.3 0.7 5.5 
Chitosan- leucine nanoparticle 
(calculated) 
63.8 24.2 8.6 3.5 3.5 0.0 
Chitosan- leucine nanoparticle 
(measured) 
73.7 22.4 2.4 0.9 0.9 6.2 
 
 
Table 2: Production yield, drug loading and entrapment efficiency of chitosan and conjugate 
nanoparticles 
Formulations Production 
Yield (%) 
Drug Loading 
(%) 
Entrapment 
efficiency (%) 
Chitosan nanoparticles 125 ± 6 16±1 38±1 
Conjugate nanoparticles 119±5 20±1 46±1 
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Table 3: Particle deposition in different stages of the TSI apparatus, recovered dose (RD) 
emitted dose (ED), and FPF for blank and drug-loaded chitosan and conjugate nanoparticles 
and fine particle dose (FPD) of DH determined by UV analysis (Data presented as mean ± 
SE, n=3). 
 
Analytical 
Methods 
Formulations RD (%) ED (%) Surface 
charge(mV)
FPF (%) FPD (mg) 
Gravimetric 
Analysis 
Blank 
Chitosan  
84±1.32 62±0.39 37.8±2.4 19±1.01 - 
Blank 
Conjugate  
86±0.73 85±0.94 39.2±0.23 24±0.8 - 
Drug-loaded 
Chitosan  
81±1.92 73±1.96 32.3±0.35 15±1.5 - 
Drug-loaded 
Conjugate  
74±2.52 79±2.52 35.2±2.3 21±0.7 - 
UV Analysis Drug-loaded 
Chitosan  
81±1.66 72±2.15 - 16±1.6 0.09±0.01 
Drug-loaded  
Conjugate  
87±2.97 79±2.39 - 21±0.7 0.31±0.02 
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Table 4: Release rate constants (k) and determination coefficients (r2) for drug release profile 
according to various kinetic models 
 
 Zero order First order Higuchi Hixson-Crowell Korsmeyer-Peppas 
Formulations k0            
(×10-2 
h-1) 
r2 k1      
(×10-2 
h-1) 
r2 kH     
(×10-2 
h-1) 
r2 K1/3    
(×10-2 
h-1) 
r2 kk-p (h-1) r2 n 
Chitosan 
nanoparticle 
0.0313 0.8868 0.0005 0.8921 0.4709 0.9808 0.0006 0.8903 3.3679 0.9611 0.0568
Conjugate 
nanoparticle 
0.0513 0.8334 0.0009 0.8593 1.1159 0.9661 0.0012 0.8509 4.4287 0.9709 0.0856
 
k0, k1, kH, k1/3 and kk-p are the apparent release rate constants of the respective mathematical 
models. n is the release exponent of the Korsmeyer-Peppas model, indicative of the 
mechanism of drug release.   
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